News

November 14, 2017


eXIthera Presents Clinical Data on Novel Small Molecule FXIa Inhibitor EP-7041 at American Heart Association


Antithrombotic EP-7041 safe and well tolerated; performed in antithrombotic test range associated with clinical efficacy and with fast onset/offset of activity

>> Read More

December 19, 2016


Capstone Therapeutics Announces Profound, Rapid LDL Cholesterol Reduction in AEM-28-14 Primate Study


Tempe, AZ – December 19, 2016 ─ Capstone Therapeutics Corp. (OTCQB: CAPS) (“the Company”) and LipimetiX Development, Inc., the Company’s drug development joint venture (“JV”) announced today that the JV’s lead commercial drug candidate, AEM-28-14, showed substantial and statistically-significant LDL cholesterol (LDLc) reductions in a hypercholesterolemic primate study at Wake Forest University.

>> Read More

Aug. 25, 2016


Capstone Therapeutics Announces That Its Joint Venture, LipimetiX Development, Inc.


TEMPE, Ariz., Aug. 25, 2016 (GLOBE NEWSWIRE) ­­ Capstone Therapeutics Corp. (OTCQB:CAPS) (“the Company”) and LipimetiX Development, Inc., the Company’s drug development joint venture (“JV”) announced today that the JV’s Series B­1 preferred stock offering totaling $1,012,000 closed on August 25, 2016. Individual accredited investors and management participated in the financing.

>> Read More

Feb. 03, 2016


Capstone Therapeutics Announces Existing Shareholder Decision Not to Extend Exclusive due Diligence Period Other OTC_CAPS


TEMPE, Ariz., Feb. 03, 2016 (GLOBE NEWSWIRE) ­­ Capstone Therapeutics Corp. (OTCQB:CAPS) (“the Company”) and LipimetiX Development, Inc., the Company’s 60% owned joint venture (“JV”) announced today that the Lenders, as defined in the Company’s Current Report on Form 8­K filed with the Securities and Exchange Commission dated December 15, 2015, informed the Company that the Lenders would not exercise their option to extend the exclusive due diligence period through March 31, 2016 by loaning Capstone a second $1 million, under the terms of the previously­reported Securities Purchase Agreement.

>> Read More

Dec. 15, 2015


Capstone Therapeutics Announces Loan From Existing Shareholder for Exclusive Due Diligence Period Other OTC_CAPS


TEMPE, Ariz., Dec. 15, 2015 (GLOBE NEWSWIRE) ­­ Capstone Therapeutics Corp. (OTCQB:CAPS) (“the Company”) and LipimetiX Development, Inc., the Company’s 60% owned joint venture (“JV”) announced today that the Biotechnology Value Fund, L.P. and other affiliates of BVF Partners L.P. ("BVF") have provided a $1 million secured loan to Company as consideration for the Company granting an exclusive period for due diligence, which may lead to an equity investment in Company of up to $10 million.

>> Read More

Oct. 14, 2015


Capstone Therapeutics Announces Allowance of U.S Patent for Treatment of Diabetes with Apo E Mimetic Peptides


TEMPE, Ariz., Oct. 14, 2015 (GLOBE NEWSWIRE) ­­ Capstone Therapeutics, Inc. (OTCQB:CAPS) ("the Company") and its (60% owned) joint venture affiliate, LipimetiX Development, Inc. ("JV"), announced today the allowance of U.S. Patent application number 12/675,089 for the use of apolipoprotein E mimetic peptides to decrease plasma glucose in patients with diabetes or insulin resistance.

>> Read More

News and Events

November 14, 2017

eXIthera Presents Clinical Data on Novel Small Molecule FXIa Inhibitor EP-7041 at American Heart Association
>> Read More

December 19, 2016

Capstone Therapeutics Announces Profound, Rapid LDL Cholesterol Reduction in AEM-28-14 Primate Study
>> Read More

Aug. 25, 2016

Capstone Therapeutics Announces That Its Joint Venture, LipimetiX Development, Inc.
>> Read More

Feb. 03, 2016

Capstone Therapeutics Announces Existing Shareholder Decision Not to Extend Exclusive due Diligence Period Other OTC_CAPS
>> Read More

Dec. 15, 2015

Capstone Therapeutics Announces Loan From Existing Shareholder for Exclusive Due Diligence Period Other OTC_CAPS
>> Read More

Oct. 14, 2015

Capstone Therapeutics Announces Allowance of U.S Patent for Treatment of Diabetes with Apo E Mimetic Peptides
>> Read More